Revenue
2022
2023
2024
2025
ZyVersa Therapeutics, Inc. (ZVSA)
Price$0.1030Cached quote
Net income
2021
2022
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2021
2022
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $1.1M | $1.8M | $3.2M | $5.4M | $5.4M | — |
| Operating expenses | $25.5M | $9.1M | $107.8M | $13.0M | $13.0M | $235,267 |
| Operating income | −$25.5M | −$9.1M | −$107.8M | −$13.0M | −$13.0M | −$235,267 |
| EBITDA | −$25.3M | −$9.1M | −$107.7M | −$13.6M | −$13.0M | — |
| Net income | −$25.0M | −$9.4M | −$98.3M | −$14.0M | −$14.0M | −$240,700 |
| Basic EPSper basic share | -$4.18 | -$8.48 | -$1,089.70 | -$346.50 | -$9.90 | — |
| Diluted EPSper diluted share | -$4.18 | -$8.48 | -$1,089.70 | -$346.50 | -$9.90 | — |
Owners
Reported shareholders